{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:42:18Z","timestamp":1792082538347,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-026-00677-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:18:48Z","timestamp":1772795928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer\u2019s disease pathophysiology and treatment effects"],"prefix":"10.1038","volume":"12","author":[{"given":"Youfang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Wildsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Charil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Reyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"677_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/psp4.12912","volume":"12","author":"H Geerts","year":"2023","unstructured":"Geerts, H. et al. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer\u2019s disease. CPT Pharmacomet. Syst. Pharmacol. 12, 444\u2013461 (2023).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"677_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/psp4.12759","volume":"11","author":"L Lin","year":"2022","unstructured":"Lin, L. et al. Quantitative systems pharmacology model for Alzheimer\u2019s disease to predict the effect of aducanumab on brain amyloid. CPT Pharmacomet. Syst. Pharmacol. 11, 362\u2013372 (2022).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"677_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/psp4.12876","volume":"12","author":"V Ramakrishnan","year":"2023","unstructured":"Ramakrishnan, V. et al. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: insights into the therapeutic mechanisms of clinical candidates. CPT Pharmacomet. Syst. Pharmacol. 12, 62\u201373 (2023).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"677_CR4","doi-asserted-by":"crossref","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 13, 80 (2021).","DOI":"10.1186\/s13195-021-00813-8"},{"key":"677_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"677_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74, 201\u2013209 (2010).","journal-title":"Neurology"},{"key":"677_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","volume":"35","author":"PC May","year":"2015","unstructured":"May, P. C. et al. The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans. J. Neurosci. 35, 1199\u20131210 (2015).","journal-title":"J. Neurosci."},{"key":"677_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41557-020-0452-1","volume":"12","author":"TCT Michaels","year":"2020","unstructured":"Michaels, T. C. T. et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer\u2019s A\u03b242 peptide. Nat. Chem. 12, 445\u2013451 (2020).","journal-title":"Nat. Chem."},{"key":"677_CR9","doi-asserted-by":"publisher","first-page":"12087","DOI":"10.1073\/pnas.1922267117","volume":"117","author":"AJ Dear","year":"2020","unstructured":"Dear, A. J. et al. Kinetic diversity of amyloid oligomers. Proc. Natl. Acad. Sci. USA 117, 12087\u201312094 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"677_CR10","first-page":"e7","volume":"7","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 7, e7 (2018).","journal-title":"Neuron"},{"key":"677_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","volume":"8","author":"M Roberts","year":"2020","unstructured":"Roberts, M. et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease. Acta Neuropathol. Commun. 8, 13 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"677_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"677_CR13","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D. & Rabinovici, G. D. The role of amyloid PET in imaging neurodegenerative disorders: a review. J. Nucl. Med. 63, 13S\u201319S (2022).","journal-title":"J. Nucl. Med."},{"key":"677_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg, L. et al. Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics 20, 195\u2013206 (2023).","journal-title":"Neurotherapeutics"},{"key":"677_CR15","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1093\/brain\/awad189","volume":"146","author":"DN Schoonhoven","year":"2023","unstructured":"Schoonhoven, D. N. et al. Tau protein spreads through functionally connected neurons in Alzheimer\u2019s disease: a combined MEG\/PET study. Brain 146, 4040\u20134054 (2023).","journal-title":"Brain"},{"key":"677_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ajpath.2017.03.011","volume":"187","author":"RE Bennett","year":"2017","unstructured":"Bennett, R. E. et al. Enhanced tau aggregation in the presence of amyloid \u03b2. Am. J. Pathol. 187, 1601\u20131612 (2017).","journal-title":"Am. J. Pathol."},{"key":"677_CR17","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1093\/brain\/awt273","volume":"136","author":"CH Andrade-Moraes","year":"2013","unstructured":"Andrade-Moraes, C. H. et al. Cell number changes in Alzheimer\u2019s disease relate to dementia, not to plaques and tangles. Brain 136, 3738\u20133752 (2013).","journal-title":"Brain"},{"key":"677_CR18","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain 140, 3286\u20133300 (2017).","journal-title":"Brain"},{"key":"677_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-05491-6","volume":"612","author":"P Yuan","year":"2022","unstructured":"Yuan, P. et al. PLD3 affects axonal spheroids and network defects in Alzheimer\u2019s disease. Nature 612, 328\u2013337 (2022).","journal-title":"Nature"},{"key":"677_CR20","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.0811698106","volume":"106","author":"RM Koffie","year":"2009","unstructured":"Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA 106, 4012\u20134017 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"677_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3233\/JAD-122038","volume":"34","author":"L Blazquez-Llorca","year":"2013","unstructured":"Blazquez-Llorca, L., Merch\u00e1n-P\u00e9rez, \u00c1., Rodr\u00edguez, J. R., Gasc\u00f3n, J. & DeFelipe, J. FIB\/SEM technology and Alzheimer\u2019s disease: three-dimensional analysis of human cortical synapses. J. Alzheimers Dis. 34, 995\u20131013 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"677_CR22","unstructured":"Bhagunde, P. et al. Brain amyloid plaque levels affect clinical progression in Alzheimer disease: assessment of amyloid PET and change in CDR-SB utilizing semi-mechanistic model. CPT Pharmacometrics Syst. Pharmacol. (in the press)."},{"key":"677_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2174\/1567205013666160401115127","volume":"13","author":"AM Di Battista","year":"2016","unstructured":"Di Battista, A. M., Heinsinger, N. M. & Rebeck, G. W. Alzheimer\u2019s disease genetic risk factor APOE-\u03b54 also affects normal brain function. Curr. Alzheimer Res. 13, 1200\u20131207 (2016).","journal-title":"Curr. Alzheimer Res."},{"key":"677_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/psp4.12862","volume":"11","author":"S Hayato","year":"2022","unstructured":"Hayato, S. et al. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacomet. Syst. Pharmacol. 11, 1578\u20131591 (2022).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"677_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr.","year":"2013","unstructured":"Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol."},{"key":"677_CR26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain 141, 1517\u20131528 (2018).","journal-title":"Brain"},{"key":"677_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"677_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"677_CR29","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman, R. J. et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1862\u20131876 (2023).","journal-title":"N. Engl. J. Med."},{"key":"677_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin, S. et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 79, 1015\u20131024 (2022).","journal-title":"JAMA Neurol."},{"key":"677_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/cpt.2536","volume":"111","author":"H Zhu","year":"2022","unstructured":"Zhu, H., Mehta, M., Huang, S. M. & Wang, Y. Toward bridging unmet medical need in early Alzheimer\u2019s disease: an evaluation of beta-amyloid (A\u03b2) plaque burden as a potential drug development tool. Clin. Pharmacol. Ther. 111, 728\u2013731 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"677_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75204-8","volume":"14","author":"KI Avgerinos","year":"2024","unstructured":"Avgerinos, K. I., Manolopoulos, A., Ferrucci, L. & Kapogiannis, D. Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. Sci. Rep. 14, 25741 (2024).","journal-title":"Sci. Rep."},{"key":"677_CR33","doi-asserted-by":"publisher","first-page":"105360","DOI":"10.1016\/j.nbd.2021.105360","volume":"154","author":"J Root","year":"2021","unstructured":"Root, J., Merino, P., Nuckols, A., Johnson, M. & Kukar, T. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 154, 105360 (2021).","journal-title":"Neurobiol. Dis."},{"key":"677_CR34","doi-asserted-by":"publisher","first-page":"e70790","DOI":"10.1002\/alz.70790","volume":"21","author":"JAK Chong Chie","year":"2025","unstructured":"Chong Chie, J. A. K. et al. Alzheimer\u2019s disease neuroimaging initiative. neurometabolic and vascular dysfunction as an early diagnostic for Alzheimer\u2019s disease and related dementias. Alzheimers Dement. 21, e70790 (2025).","journal-title":"Alzheimers Dement."},{"key":"677_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tem.2023.05.002","volume":"34","author":"LG Yang","year":"2023","unstructured":"Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol. Metab. 34, 430\u2013445 (2023).","journal-title":"Trends Endocrinol. Metab."},{"key":"677_CR36","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuron.2024.11.018","volume":"113","author":"A Flury","year":"2025","unstructured":"Flury, A. et al. A neurodegenerative cellular stress response linked to dark microglia and toxic lipid secretion. Neuron 113, 554\u2013571.e14 (2025).","journal-title":"Neuron"},{"key":"677_CR37","doi-asserted-by":"publisher","first-page":"12453","DOI":"10.1073\/pnas.1811195115","volume":"115","author":"Y Cao","year":"2018","unstructured":"Cao, Y., Lei, X., Ribeiro, R. M., Perelson, A. S. & Liang, J. Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proc. Natl. Acad. Sci. USA 115, 12453\u201312458 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"677_CR38","doi-asserted-by":"publisher","first-page":"18445","DOI":"10.1073\/pnas.1001455107","volume":"107","author":"Y Cao","year":"2010","unstructured":"Cao, Y., Lu, H. M. & Liang, J. Probability landscape of heritable and robust epigenetic state of lysogeny in phage lambda. Proc. Natl. Acad. Sci. USA 107, 18445\u201318450 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"677_CR39","doi-asserted-by":"publisher","first-page":"S400","DOI":"10.1016\/j.jalz.2013.10.003","volume":"10","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 10, S400\u2013S410 (2014).","journal-title":"Alzheimers Dement."},{"key":"677_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/neuro.09.031.2009","volume":"3","author":"S Herculano-Houzel","year":"2009","unstructured":"Herculano-Houzel, S. The human brain in numbers: a linearly scaled-up primate brain. Front. Hum. Neurosci. 3, 31 (2009).","journal-title":"Front. Hum. Neurosci."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00677-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00677-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00677-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:33:42Z","timestamp":1776663222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00677-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1038\/s41540-026-00677-4","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors were employees of Eisai Inc. when this work was conducted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}